ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation

Rationale: Immune checkpoint inhibitors (ICIs) against the PD-1/PD-L1 pathway showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those with activating epidermal growth factor receptor (EGFR) mutations. Elucidation of the mechanisms underlying EGFR-mediated tumor imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaozheng, Gao, Aiqin, Zhang, Fang, Yang, Zijiang, Wang, Shuyun, Fang, Yuying, Li, Juan, Wang, Jingnan, Shi, Wenjing, Wang, Linlin, Zheng, Yan, Sun, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847666/
https://www.ncbi.nlm.nih.gov/pubmed/33537094
http://dx.doi.org/10.7150/thno.52435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847666/
https://www.ncbi.nlm.nih.gov/pubmed/33537094
http://dx.doi.org/10.7150/thno.52435

Ejemplares similares